Compare IGIC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGIC | CERT |
|---|---|---|
| Founded | 2001 | 2008 |
| Country | Jordan | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2020 |
| Metric | IGIC | CERT |
|---|---|---|
| Price | $26.43 | $8.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $28.00 | $11.67 |
| AVG Volume (30 Days) | 87.7K | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $0.13 | $4.18 |
| Revenue Next Year | $2.54 | $5.39 |
| P/E Ratio | $9.05 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $20.82 | $4.45 |
| 52 Week High | $29.59 | $13.88 |
| Indicator | IGIC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 58.49 |
| Support Level | $24.51 | $7.86 |
| Resistance Level | $27.34 | $8.89 |
| Average True Range (ATR) | 0.66 | 0.29 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 41.67 | 53.04 |
International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.